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Translational relevance 
PTBP1 expression positively correlates with NMIBC progression and with worse clinical 
outcome of patients. Mechanistically, PTBP1 regulates pro-survival features and modulates 
alternative splicing of bladder cancer-related genes in NMIBC cell lines and patient 
specimens. Thus, PTBP1 expression and its splicing signature can represent novel outcome-
predictor markers for NMIBC. 
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Abstract  
Purpose: Non-muscle invasive bladder cancer (NMIBC) is a malignant disease characterized 
by high heterogeneity, which corresponds to dysregulated gene expression and alternative 
splicing (AS) profiles. Bioinformatics analyses of splicing factors potentially linked to 
bladder cancer progression identified the heterogeneous nuclear ribonucleoprotein I (i.e. 
PTBP1) as candidate. This study aimed at investigating whether PTBP1 expression associates 
with clinical outcome in NMIBC patients.  
Experimental Design: A cohort of 152 patients presenting primary NMIBC (pTa-pT1) was 
enrolled. Primary NMIBCs were assessed for PTBP1 expression by immunohistochemistry 
(IHC) and the results were correlated with clinical data using Kaplan–Meier curves and Cox 
regression analyses. Cell proliferation and survival assays were performed to assess the 
function of PTBP1. Furthermore, the impact of PTBP1 on the AS pattern of specific bladder 
cancer-related genes was investigated in cancer cell lines and in patient’s specimens. 
Results:  Public datasets querying highlighted a positive correlation between PTBP1 
expression and NMIBC progression, which was then confirmed by IHC analysis. High 
PTBP1 expression was associated with worse clinical outcome in terms of incidence of tumor 
relapse and survival in NMIBC patients. Interestingly, down-regulation of PTBP1 in bladder 
cancer cell lines affected pro-survival features. Accordingly, PTBP1 modulated AS of bladder 
cancer-related genes in cell lines and patient’s specimens.  
Conclusion(s):  PTBP1 expression correlates with disease progression, poor prognosis and 
worse survival in NMIBC patients. Down-regulation of PTBP1 expression affects pro-
survival features of bladder cancer cells and modulates AS of genes with relevance for 
bladder cancer, suggesting its role as outcome-predictor in this disease.  
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Introduction 
Bladder cancer is the sixth most common cancer in men, with an estimated 429,800 
cases diagnosed in 2012 and 165,100 deaths for the disease worldwide (1). It is typically 
subdivided in three main categories on the basis of management goals and prognosis: non-
muscle invasive bladder cancer (NMIBC), muscle invasive bladder cancer and metastatic 
bladder cancer. NMIBC represents the most frequent form and includes carcinoma in situ 
(stage Tis), papillary lesions confined to the urothelium (stage Ta) or invading the lamina 
propria (stage T1) (2). Complete trans-urethral resection of bladder tumors (TURBT) is the 
routine initial diagnostic and therapeutic step in management. However, over 50% NMIBCs 
will recur and up to 25% will progress to muscle-invasive disease (3). Due to probability of 
recurrence and progression, NMIBC requires repeated surveillance and intervention and is 
among the most expensive cancers to treat from diagnosis to death (4). 
Criteria assessing patient and tumor characteristics provide valuable information about 
disease recurrence, progression and proposed treatments. The European Organisation for 
Research and Treatment of Cancer (EORTC) electronic risk calculator 
(http://www.eortc.be/tools/bladdercalculator) is commonly used to assess recurrence and 
progression potential of newly diagnosed cancers. The parameters used are tumor size and 
number, pathological stage and grade, presence of carcinoma in situ (CIS), and prior 
recurrence rate (5). Ease of use and absence of expensive molecular tests represent the main 
advantages of this and other scoring models (6,7). However, reproducibility of pathologic 
stage and grade is modest and remains a critical clinical concern.  
Strong efforts are currently aimed at identifying molecular markers with robust 
diagnostic and prognostic value for NMIBC (8). Although several molecular markers are 
currently approved by the U.S. Food and Drug Administration (FDA) and its European 
counterpart (9), their value in predicting NMIBC recurrence and progression is limited and 
none of them is recommended by clinical guidelines (10). Thus, identification of valuable 
markers or therapeutic targets that reduce the likelihood of recurrence and/or progression is a 
clinical priority for NMIBC management.  
 Dysregulation of splicing is emerging as a key feature of human cancers with 
therapeutic perspective (11). Splicing leads to excision of introns and ligation of exons from 
the precursor mRNA (pre-mRNA) and is orchestrated by the spliceosome, a macromolecular 
machinery composed of five small nuclear ribonucleoprotein particles and hundreds of 
auxiliary proteins (12). When the exon-intron boundaries (splice sites) display high levels of 
conservation, exons are almost always included in the mRNA (constitutive exons), whereas 
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exons lacking strong consensus sequences are subjected to regulation (alternative exons). In 
this case, exon recognition is tuned by trans-acting splicing factors (SFs) that bind to cis-
regulatory sequences. The interplay between antagonistic SFs determines whether a target 
exon is included or skipped through a process named alternative splicing (AS) (12). Since 
most splice isoforms engage specific interactions and behave as distinct proteins (13), AS 
increases the coding potential of genomes and represents an evolutionary advantage (14). 
However, its flexible regulation is prone to errors and defective splicing contributes to 
neoplastic transformation (11,13). In this regard, splicing inhibition is envisioned as an 
effective anti-cancer therapy, as many tumors are very sensitive to this approach (11). 
The main classes of SFs are the serine-arginine (SR) proteins and the heterogeneous 
nuclear ribonucleoproteins (hnRNPs), which often act antagonistically in AS regulation (12). 
Members of both classes, like SRSF1 (15,16) and hnRNPA1, A2 and I (also known as 
PTBP1) (17,18), were shown to play oncogenic functions. Notably, although AS 
dysregulation has been reported also in bladder cancer (19), limited information is available 
regarding the SFs responsible for this process and their possible association with prognosis. 
Herein, we have performed bioinformatics search for SR and hnRNP proteins associated with 
bladder cancer progression. Our study identified hnRNPI/PTBP1 as a factor linked to disease 
progression and suggest PTBP1 as a new prognostic factor and possible therapeutic target for 
NMIBC progression. 
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Materials and Methods 
Bioinformatics analysis 
R2 genomics platform (http://r2.amc.nl) and Oncomine database (www.oncomine.org) were 
used to evaluate the association of splicing factors with bladder cancer grade using Hoglund, 
Dyrskjot and Sanchez-Carbayo datasets (20-22). 
Study population and ethics statement 
Patients with histologically proven primary pTa and pT1 bladder urothelial carcinoma were 
enrolled in the study. Inclusion criteria were: age >18 years, adequate bone-marrow reserve, 
normal renal and liver function and Eastern Cooperative Oncology Group performance status 
between 0 and 2 (23). Exclusion criteria were: previous bladder cancer; non-urothelial 
carcinomas; previous or concomitant urinary-tract carcinoma in situ and urothelial carcinoma 
of the upper urinary tract and urethra; bladder capacity less than 200 mL; untreated urinary 
tract infection; severe systemic infection; urethral strictures preventing endoscopic 
catheterization; previous radiotherapy to the pelvis; other concurrent chemotherapy, 
radiotherapy, treatment with biological response modifiers; other malignant diseases within 5 
years of trial registration (except for adequately treated basal-cell or squamous-cell skin 
cancer, and in situ cervical cancer); pregnancy; other factors precluding study participation.  
All patients underwent TURBT of endoscopically detected tumors, ensuring that muscle was 
included in resected samples, as specified by European Association of Urology guidelines (2). 
Before TURBT, a cold-cup biopsy of apparently non-tumor-bearing and tumor were taken 
and stored at -80°C until analysis. Tumors were staged in accordance with the TNM 
classification (24) and biopsies were graded according to WHO classifications (25). Risk 
categories for recurrence and progression were assessed in accordance with EORTC risk 
tables for NMIBC (5). Within 6 hours of TURBT, patients received a single intravesical 
instillation of 40 mg mitomycin. 4-6 weeks after TURBT, patients without muscle in resected 
samples, positive or suspect cytology, carcinoma in situ, stage T1, or grade 3 tumors 
underwent restaging transurethral resection, random cold-cup bladder and prostatic urethra 
biopsies, and upper-urinary-tract imaging. No adjuvant intravesical therapy was given to 
patients with low-risk NMIBC. Patients with intermediate-risk and high-risk NMIBC were 
scheduled to receive adjuvant long-term intravesical chemotherapy with mitomycin, or 
immunotherapy with bacillus Calmette-Guerin, starting ~3 weeks after TURBT procedures. 
Patients were followed-up with abdominal ultrasonography, urinary cytology and cystoscopy 
every 3 months for 2 years, twice during the third year, and yearly thereafter. 
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All procedures performed in studies involving human participants were in accordance with 
the ethical standards and with the Declaration of Helsinki. The institutional review board 
approved the study design and all enrolled patients signed an informed consent form 
providing details of treatments.  
Immunohistochemistry and statistical analysis 
PTBP1 immunohistochemistry (IHC) was performed on formalin-fixed, paraffin-embedded 
tissues obtained from 152 primary pTa-pT1 NMIBC patients. Antigen was retrieved by 
microwave treatment at 750 W for 10 min in 10 mM sodium citrate buffer (pH 6.0). Sections 
were incubated for 60 min at room temperature with 1:500 anti-PTBP1 antibody (sc-16547, 
Santa Cruz Biotechnology, Santa Cruz, CA), or non-immune serum as control, using the 
LSAB signal amplification kit (K0690, Dako, Glostrup, Denmark). PTBP1 expression was 
defined by presence of nuclear staining in tumor cells. IHC analysis was done in blind by two 
pathologists (M.P., R.L.) unaware of clinic-pathologic information, with 80% concordance in 
evaluation. 30 cases (19.7%) in which evaluation of PTBP1 expression differed by >10% 
between the two observers were re-evaluated. After consensus was achieved, the absolute 
inter-observer variability (mean difference% ± SD) recorded was 3.95% ± 3.14. 
The relationship between PTBP1 expression and clinic-pathological parameters were 
investigated by Pearson’s 2 test or Fisher’s exact test. All clinical analyses were performed 
on an intent to treat basis. Primary endpoint was disease-free interval (DFS), defined as time 
from initial TURBT randomisation to first cystoscopy noting recurrence. Secondary endpoints 
were progression free (PFS), overall (OS), and disease specific survival (DSS). Starting from 
initial TURBT: PFS was defined as time until onset of muscle invasive disease as recorded by 
pathological assessment of transurethral-resection samples or biopsy samples; OS as time 
until death from any cause; DSS as time until death from bladder cancer. Patients without 
recurrence or progression were censored at the last cystoscopy, and those lost to follow-up 
were censored at the last known day of survival. Endpoints were studied by the Kaplan-Meier 
method and comparisons were made by the log-rank test. Association of PTBP1 expression 
with outcome, adjusted for other prognostic factors, was tested by Cox’s proportional hazards 
model. Appropriateness of the proportional hazard assumption was assessed by plotting the 
log cumulative hazard functions over time and checking for parallelism. SPSS Version 15.0 
(SPSS, Chicago, IL) was used throughout and P<0.05 was considered statistically significant. 
Cell cultures and manipulations 
Bladder cancer cell lines, RT4, RT112 and EJ (26), were purchased and kindly provided by 
Dr. Francesca Velotti (La Tuscia University, Viterbo, Italy), and further authentication has not 
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been performed. Bladder cancer cell lines were cultured in RPMI 1640 medium (LONZA) 
supplemented with 10% FBS (Gibco) at 37°C with 5% CO2. Mycoplasma contamination of 
cell cultures was routinely tested by Hoechst 33258 stain (27), every two-three weeks. Upon 
thawing, bladder cancer cell lines have been subcultured for not more than 15 passages. RNAi 
experiments, protein extractions and immunofluorescence analyses were performed as 
previously described (28,29).  
For clonogenic, cell cycle, proliferation and adhesion assays, cells were silenced twice with 
CTRL or PTBP1 siRNAi (80nM). Colony‑forming assay was performed as described (30). 
Briefly, 24 hrs after transfection, 400 cells were plated in 60mm dishes and cultured for one 
week. After fixation-staining for 30min with glutaraldehyde 6.0% (vol/vol)/crystal violet 
0.5% (wt/vol) solution, colonies with n >50 cells were counted. 
For cell cycle/subG1 analyses, cells were pulse-labeled with 10 μM BrdU for 45min before 
harvesting and fixed with a 30% phosphate-buffered saline/70% ethanol solution for 30 
minutes in ice. Hypodiploid events and cell cycle were evaluated by flow cytometry using 
propidium iodide (PI) staining (20 μg/ml) and anti-BrdU antibody in the presence of 13 
Kunitz units/ml ribonuclease A as described (31). 15x10
3
 events were counted with 
FacsCalibur flow cytometer (Becton Dickinson) and analyzed using Flow-Jo program 
(Becton Dickinson).  
Cell death was evaluated by staining for Annexin V (1g/ml) and PI (1g/ml) (eBioscience) 
and analyzed by flow cytometry (FACSCanto; BD Biosciences). The combination of Annexin 
V and PI staining discriminates live cells (Annexin V/PI double negative) from apoptotic cells 
(Annexin V/PI double positive). 
Splicing assay, UV-crosslinked RNA immunoprecipitation (CLIP) and qRT-PCR 
analyses  
RNA was extracted from cells using Trizol reagent (Invitrogen) and PCR analyses were 
performed as described (28,29). Primers are listed in Supplementary Information. 
Quantitative expression level of CD44 variable exons was calculated by ΔCt method relative 
to total CD44. CLIP assays were performed as extensively described and RNA associated 
with PTBP1 was represented as percentage of input (32). 
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Results  
PTBP1 expression correlates with poor prognosis in tumor bladder patients. 
Public datasets (R2 genomics analysis and visualization platform, http://r2.amc.nl) were 
queried for correlation between expression of SR proteins and hnRNPs and bladder cancer 
progression. Expression of PTBP1 (i.e. hnRNPI) was found to significantly correlate with 
disease progression in the Hoglund cohort including 308 patients (Fig. 1A; Supplementary 
Fig. S1A). PTBP1 expression also resulted significantly higher in invasive T1 stage compared 
to non-invasive Ta stage cancers (Fig. 1B). Analysis of two other datasets 
(https://www.oncomine.org: Dyrskjot and Sanchez-Carbayo datasets) confirmed that PTBP1 
expression is increased in infiltrating and superficial bladder cancers compared to normal 
tissue (Supplementary Fig. S1B-D). More importantly, Kaplan-Meier analysis highlighted 
significant association between high PTBP1 mRNA expression and low OS probability 
(p<0.001; Fig. 1C). By contrast, expression of other SFs was either unchanged or slightly 
affected, or associated only with G3 tumors (i.e. hnRNPA2B1, hnRNPC, hnRNPL, SRSF7 
and SRSF10; Fig. 1A; Supplementary Fig. S1A).  
To determine whether the bioinformatics analysis of mRNA expression levels in public 
databases represents a valuable tool to identify proteins with oncogenic potential, PTBP1 up-
regulation was also tested at the protein level by Western blot analysis using a cohort of 
surgical tumor (T) and non-tumor (NT) specimens from 50 NMIBC patients. PTBP1 protein 
was significantly increased in the neoplastic lesions compared to the adjacent non-neoplastic 
urothelium (p=0.003; Fig. 2A). To extend this analysis, we enrolled a cohort of 178 patients. 
After initial TURBT, we excluded 13 patients because of concomitant urothelial carcinoma of 
the upper urinary tract (n=3) and prostatic urethra (n=4), histology other than pure urothelial 
carcinoma (n=4), and consent refusal (n=2). Restaging TURBT was performed in 69 patients 
(54 with high-risk disease and 15 with multifocal intermediate-risk disease) and histological 
findings showed that 10 patients with residual stage pTa or pT1 tumor were eligible, whereas 
9 with concomitant carcinoma in situ (pTis) and 4 with muscle invasive disease (stage pT2) 
were ineligible. Of the remaining 152 patients (see clinical features and tumor characteristics 
in Table 1), seventy-four cases (48.7%) were non-invasive papillary carcinoma (pTa) and 
seventy-eight (51.3%) were tumors invading sub-epithelial connective tissue (pT1). 
According with EORTC risk tables classification for NMIBC (5), the cancer progression risk 
was low in 27 cases (17.7%), intermediate in 70 cases (46.1%) and high in 54 cases (36.2%; 
Table 1). 
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Percentage of PTBP1-positive cells was significantly higher in tumor specimens with respect 
to the non-neoplastic urothelium (Supplementary Fig. S2A), and it ranged from 3 to 98% 
(mean±SE=40.7±2.9) in tumor tissues. Examples of PTBP1 expression in patients with low-, 
intermediate-, and high-risk of cancer progression are shown in Fig. 2B. Notably, significant 
increase in PTBP1 expression was associated with risk of cancer progression (Fig. 2C).  
To dichotomize PTBP1 expression, a cut-off of 6% positive cells was chosen according to the 
receiver operating characteristic (ROC) curve analysis (AUC=0.779, p<0.001; Supplementary 
Fig. S2B,C). Tumors with >6% positive cells (n=105) were considered PTBP1High and those 
with ≤6% positive cells (n=47) were PTBP1Low. PTBP1 expression directly correlated with 
pT1 tumors (p<0.001), grade 3 tumors (p<0.001), and tumors with high risk of progression 
(p<0.001) (Table 1). We also found direct correlation between PTBP1
High
 and the number of 
patients experiencing tumor recurrence (p=0.001), cancer progression (p=0.021), overall 
mortality (p=0.047), and cancer mortality (p=0.029) (Table 1). Furthermore, Kaplan-Meier 
analysis indicated that PTBP1
High
 expression was significantly associated with lower DFS, 
PFS, OS, and DSS rates (Fig. 2D). In particular, survival rates for patients with PTBP1
High
 
and PTBP1
Low
 tumors were 39.0% vs. 68.1% (DFS; p<0.001), 89.5% vs. 100.0% (PFS; 
p=0.023), 57.1% vs. 74.5% (OS; p=0.006), and 90.5% vs. 100.0% (DSS; p=0.024). Lastly, 
univariate analysis showed that PTBP1
High
 was significantly associated with poor DFS 
(hazard ratio [HR], 2.6; 95% confidence interval [CI], 1.5-4.6; p=0.001), and OS (HR, 2.4; 
95% CI, 1.3-4.5; p=0.008) (Supplementary Table S1). Multivariate analysis demonstrated that 
the only factors negatively impacting on survival were tumor grade (DFS; p=0.018), and age 
of patients at diagnosis (OS; p<0.001) (Supplementary Table S2).  
These observations confirm the predictive value of our bioinformatics analysis of deposited 
mRNA expression levels and highlight PTBP1 as a novel marker of poor prognosis and 
disease progression, thus suggesting its oncogenic role in bladder cancer.  
 
PTBP1 depletion affects pro-survival features of bladder cancer cells.  
To investigate whether PTBP1 was functionally relevant for bladder cancer cells, we knocked 
down its expression by two rounds of transfection with siRNAs (siPTBP1) and obtained an 
almost complete depletion in three bladder cancer cell lines (RT4, RT112 and EJ; 
Supplementary Fig. S3A). Silencing of PTBP1 expression significantly reduced growth of all 
cell lines as measured by clonogenic assays (Fig. 3A; Supplementary Fig. S3B). 
Cytoflourimetric analysis of the cell cycle indicated that PTBP1 knockdown resulted in the 
reduction of cells engaged in active S phase (BrdU-positive cells) and in the concomitant 
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increase of cells in inactive S phase (not incorporating BrdU but stalled with DNA content 
between 2N and 4N) (Fig. 3B; Supplementary Fig. S3C). Moreover, depletion of PTBP1 
dramatically increased the population of cells with a sub-G1 DNA content (Fig. 3C; 
Supplementary Fig. S3D), suggesting that stalling in S phase was followed by cell death. 
Indeed, double staining with Annexin V and PI (Fig. 3D; Supplementary Fig. S3E) and 
immunofluorescence analysis of caspase-3 cleavage (Supplementary Fig. S3F) confirmed the 
significant increase in apoptotic cells after depletion of PTBP1 in all three cell lines.  
To test whether depletion of PTBP1 affects the response of bladder cancer cells to 
chemotherapeutic treatment with mitomycin C, we used a suboptimal concentration of the 
drug (0.03 M) and set out conditions to reduce PTBP1 without strongly affecting cell 
survival (lower siRNA concentration and single round of transfection). Under these 
conditions, silencing of PTBP1 enhanced the cytotoxic effect of mitomycin C on bladder 
cancer cells death, as indicated by double staining with Annexin V and PI (Fig. 3E; 
Supplementary Fig. S3G) and analysis of caspase 3 cleavage (Supplementary Fig. S3H).  
These results demonstrate that PTBP1 favors bladder cancer cell proliferation and survival 
and that it protects them from chemotherapeutic treatment.  
 
PTBP1 regulates bladder cancer-relevant splice variants 
PTBP1 is best known for its role in AS (33) and expression of oncogenic splice variants has 
been positively associated with disease progression in bladder cancer patients (19,34). We 
noted that some of these AS events are potential PTBP1 targets (Supplementary Table S3) 
(35,36). To test whether PTBP1 promotes the expression of these pro-oncogenic variants in 
bladder cancer cells, we examined its impact on the splicing pattern of eight genes. The 
oncogenic splice variants of seven of these genes were expressed in all three cell lines, 
whereas CD44 alternative variants were detected only in RT112 cells (Supplementary Fig. 
S4A,B). Notably, knockdown of PTBP1 reverted splicing of the pro-oncogenic variant of all 
its potential bladder cancer-related target genes (Fig. 4A,B) (35,36). On the other hand, exon 
3 in PIK4CB and exon 5-6 in LRRFIP2, which are not its predicted target exons 
(Supplementary Table S3), were unaffected by PTBP1 depletion.  
In addition to being involved in cell proliferation (PKM and NUMB) or cell death (FAS), 
which are affected by PTBP1 depletion (Fig. 3), several of the PTBP1 target genes encode for 
proteins that regulate the cell cytoskeleton and adhesion (ACTN1, MACF1, TPM1, CD44 and 
CTNND1). Accordingly, we found that knockdown of PTBP1 impaired cell adhesion in 
bladder cancer cell lines (Supplementary Fig. S4C), indicating that changes in the splicing 
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pattern of these genes may be functionally relevant. In this regard, CD44 is a prototypic 
example of AS-regulated gene. It contains nineteen exons, nine of which (V2-V10) are 
alternative spliced to yield multiple variants (CD44v) that encode for variable extracellular 
ligand-binding domains of this trans-membrane glycoprotein and whose inclusion correlates 
with tumor progression and metastasis (37). To investigate which of the variable CD44 exons 
is regulated by PTBP1, we performed semi-quantitative PCR (sqPCR) analyses in RT112 
cells. Interestingly, inclusion of variable exons between v2 and v7 was reduced in cells 
depleted of PTBP1, whereas that of other variable exons (v8 to v10) was not (Supplementary 
Fig. S5A). Quantitative PCR (qPCR) confirmed this exon-specific regulation in PTBP1-
depleted cell (Supplementary Fig. S5B).  
 
PTBP1 directly binds in proximity of regulated exons in bladder cancer cells 
To test whether PTBP1 plays a direct role in the regulation of its target exons, we investigated 
PTBP1 recruitment on pre-mRNAs in vivo by performing UV-crosslink and RNA 
immunoprecipitation (CLIP) assays (32). PTBP1 exerts a position-dependent effect on AS by 
promoting exon inclusion when it binds in the downstream intron and exon skipping when it 
binds in the upstream intron (Supplementary Fig. S5C,D upper panels) (35,36). Thus, CLIP 
experiments were performed in presence of RNase I (fragment size ~200bp) (32) and we 
analyzed PTBP1 recruitment near the downstream intron of the positively regulated exon v7 
of CD44 and exon 99 of MACF1 (Supplementary Fig. S5C) and the upstream intron of the 
negatively regulated exon 6a of TPM1 and exon 2 of CTNND1 (Supplementary Fig. S5D). In 
both cases, we detected a significant enrichment of PTBP1 binding in the target regions with 
respect to non regulated exons (Supplementary Fig. S5C,D). These results demonstrate that 
PTBP1 specifically binds target exons in vivo and highlight its direct role in AS regulation of 
genes with strong relevance for bladder cancer.  
 
PTBP1 expression associates with CD44 splicing regulation in bladder cancer patients 
To evaluate whether regulation of splicing by PTBP1 was also detected in NMIBC 
specimens, we performed qPCR analysis of CD44 variable exons that are regulated (v5 and 
v7) or not (v9) by PTBP1. We selected 18 patients with variable PTBP1 levels (0-95% 
positive cells in IHC) from the cohort (Fig. 5A). Strikingly, PTBP1 expression was positively 
correlated with inclusion of its target exons v5 and v7, whereas the PTBP1-insensitive v9 
exon was not significantly associated (Fig. 5B). These results strongly indicate that PTBP1 
expression influences splicing outcome in bladder cancer patients. 
Research. 
on July 18, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 16, 2018; DOI: 10.1158/1078-0432.CCR-17-3850 
 13 
Discussion 
 
NMIBC mortality rate and management costs are strikingly high, underlining the need for 
valuable prognostic markers and therapeutic targets. In this regard, the splicing signature of 
human cancers is recently emerging as a sophisticated marker to distinguish tumor subtypes 
and precisely stratify patients (38). Herein, an unbiased approach to identify SFs with 
prognostic value in NMIBC undertaken by querying public databases has highlighted PTBP1 
as a key predictive factor. We report that PTBP1 expression levels positively associate with 
disease progression and worse prognosis in patients. Accordingly, PTBP1 promotes pro-
survival features of bladder cancer cells and favors splicing of oncogenic variants in both cell 
lines and patients. Thus, our study shows the predictive value of bioinformatics analysis of 
deposited gene expression datasets. Furthermore, it uncovers an oncogenic role for PTBP1 in 
NMIBC and identifies new potential prognostic and therapeutic targets for this disease.  
Aberrant splicing regulation often confers selective advantage to tumor cells by favoring 
oncogenic splice variants of cancer-related genes (13,39,40). For instance, up-regulation of 
PTBP1 in human cancer cells affected glycolytic metabolism by promoting splicing of the 
PKM2 variant (17), leading to acquisition of chemotherapy resistance in pancreatic cancer 
(18). Likewise, we found that knockdown of PTBP1 in bladder cancer cells augmented the 
cytotoxic effects of mitomycin C. More importantly, PTBP1 expression level exhibits a 
strong prognostic value in bladder cancer, as we found a significant correlation between 
PTBP1 expression, disease progression and worse outcome in a relatively large cohort of 
patients. Indeed, although, multivariate analysis did not identify PTBP1 expression as an 
independent predictor of outcome, its expression level is included among the variables that 
impact on disease progression and outcome, while Kaplan-Meier curves revealed that high 
expression of PTBP1 correlates with poor DFS, PFS, OS and DSS. These observations reveal 
that PTBP1 can be considered a valuable marker to stratify NMIBC patients in term of risk 
prediction and evaluation of its expression levels could support the current histological 
classification and improve clinical evaluation of patients. This information may also help 
guiding clinical decisions regarding the follow-up, such as choosing between conservative 
adjuvant therapy or more aggressive treatment strategies. 
We observed a 2 to 3-fold increase of PTBP1 expression in bladder cancer through public 
datasets analysis. Although this change in expression might appear limited, comparable small 
changes in expression of other splicing factors were previously shown to trigger oncogenic 
transformation, like in the case of SRSF1 (15,16). On the contrary, strong up-regulation of 
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splicing factors can be toxic for the cell (15,41). Thus, the reported increase in expression of 
PTBP1 in bladder cancer might be sufficient for its oncogenic function. Nevertheless, we 
cannot rule out the possibility that post-transcriptional regulation of PTBP1 also contributes 
to its oncogenic potential. For instance, alternative usage of exon 9 generates PTBP1 isoforms 
showing different target specificity and splicing activity (42). This regulation might impact on 
the oncogenic role of PTBP1 in bladder cancer and might also influence the multivariate 
analysis. However, since antibodies specific for these PTBP1 isoforms are not available and 
no data regarding isoform-specific expression was deposited in the public datasets, we could 
not investigate this aspect in our cohort of patients.  
Expression of pro-oncogenic splice variants is associated with bladder cancer progression 
(19). We noted that several of these bladder-cancer regulated genes were potential target of 
PTBP1. Accordingly, knockdown of PTBP1 expression readily reverted splicing of these 
genes to the less oncogenic variant. Moreover, we report a positive correlation between the 
expression level of PTBP1 and the inclusion of variable exons v5 and v7 of CD44 in NMIBC 
patient’s specimens. Based on these observations, we hypothesize that the relationship 
between AS changes in these genes and bladder cancer progression might rely on PTBP1 
expression. PTBP1 likely exerts a direct effect on these targets, as we detected its recruitment 
in proximity of the regulated exons in bladder cancer cells. Notably, PTBP1-regulated genes 
encode for proteins related to cell survival (FAS), proliferation (NUMB, PKM), cytoskeleton 
organization (ACTN1, MACF1, TPM1 and CTNND1) and interaction with the extracellular 
matrix (CD44). Furthermore, depletion of PTBP1 affected proliferation, survival and 
adhesion of bladder cancer cells, suggesting a causative role for this SF in oncogenic features 
of NMIBC cells. For instance, the increase in apoptosis observed in absence of PTBP1 may 
rely on a splicing switch in favor of the pro-apoptotic and membrane-associated FAS variant 
(+E6). By contrast, repression of exon 6 inclusion by PTBP1 generates a soluble pro-survival 
isoform of FAS (sFAS) (43). Likewise, PTBP1 promotes inclusion of variable exon v6 in 
CD44 and this isoform promotes stemness and metastasis in colorectal cancer cells (44). 
Increased inclusion of CD44 variable exons has been reported in bladder cancer (34,45,46). 
Our study now correlates inclusion of variable exons v5 and v7 with PTBP1 expression in 19 
NMIBC patients, suggesting that deregulation of CD44 AS in bladder cancer may be directly 
caused by altered expression of PTBP1. Noteworthy, although we focused on PTBP1 splicing 
targets with direct relevance for bladder cancer, our findings do not rule out possible effects 
of PTBP1 on other variants of the same or other genes in this disease.  
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In conclusion, our study shows that up-regulation of PTBP1 in bladder cancer cells alters their 
transcriptome in favor of pro-oncogenic splice variants and correlates with worse outcome in 
patients. Thus, we suggest that PTBP1 expression and its splicing signature represent novel 
outcome-predictor markers for NMIBC.  
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Figure legends 
Figure 1. mRNA expression level of the splicing factor PTBP1 is increased in bladder 
tumor. Analysis of the expression of splicing factors in tumor bladder patients at stage G1 
versus stage G2 and stage G3 (A) and at stage Ta (non-invasive papillary carcinoma) versus 
stage T1 (invasive carcinoma) (B). Boxes indicate the median (horizontal line); Whiskers, 
distances from the largest and smallest value to each end of the box; Dots, outliers. Mean 
values were compared with the two-tailed unpaired t-test. Data used for the analysis are from 
GSE 32894 Tumor Bladder-Hoglund-dataset (308 patients) deposited in R2 genomics 
analysis and visualization platform (http://r2.amc.nl). ns=no significance; *p≤0.05; **p≤0.01; 
*** p≤0.001. C) Kaplan-Meier overall survival analysis of the total Hoglund cohort based on 
the cut-off value of PTBP1 expression levels calculated by the R2 system. The difference 
between the curves for PTBP1 high and PTBP1 low groups were compared by log-rank test.  
 
Figure 2. PTBP1 expression correlates with bladder cancer patient outcome. A) 
Representative western-blot analysis of PTBP1 expression in tumor (T) and adjacent non-
tumor (NT) surgical specimens from 4 of the 50 NMIBC patients examined (upper panel). 
Tubulin was used as loading control. Densitometric analysis of PTBP1 expression relative to 
tubulin in non-tumor and tumor specimens is shown in the dots graph below (n=50; 
**p<0.001, independent-sample t-test). B) Representative imagines of IHC analysis of PTBP1 
expression in two patients with low- (1,2), intermediate- (3,4), and high- (5,6) risk of 
progression. C) Expression of PTBP1 in NMIBC patients according to risk of cancer 
progression. The expression of PTBP1 was assessed by IHC analysis of paraffin-embedded 
sections (Mean percent of positive tumor cells ± Standard Error; **p <0.001, independent-
sample t-test).  D) Kaplan-Meier disease free survival (DFS), progression free survival (PFS), 
overall survival (OS), and disease specific survival (DSS) analyses of 152 NMIBC patients 
stratified in high (solid gray line) and low (dashed black line) PTBP1 expression levels in 
tumor tissue. Statistical analysis was performed by the Long-rank test.  
 
Figure 3.  Modulation of PTBP1 expression affects pro-survival features in bladder 
cancer cells. A) Representative images of clonogenic assay performed with RT4 bladder 
cancer cells transfected twice with CTRL (siCTRL) or PTBP1 (siPTBP1) siRNAs. Bar graph 
represents the percentage of colonies formation with respect to siCTRL cells [set as 100%; 
mean± standard deviation (SD) of three independent experiments].  B,C) Representative 
Research. 
on July 18, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 16, 2018; DOI: 10.1158/1078-0432.CCR-17-3850 
 20 
bivariate plot profiles of cytometric analysis showing DNA content (propidium iodide, PI) 
versus bromodeoxyuridine (BrdU) incorporation (B) and plot profiles of PI incorporation (C). 
RT4 cells were pulse labeled with BrdU for 45 min and successively stained with BrdU 
antibody and PI. G1, S, G2 and inactive S (S inac) phase gates (square boxes) and the 
percentage of cells at each phase are indicated (B). Bar graphs show the percentage of cells in 
S and inactive S (B) and sub-G1 (C) phases. D,E) Representative plot profiles of Annexin 
V/PI cytometric analysis of RT4 cells transfected twice (D) or once (E) with the indicated 
siRNAs and treated (E) or not (D) with suboptimal amount of mitomycin C (0.03 µM) for 
24hrs. Bar graphs represent the percentage of double positive Annexin V and PI cells (mean± 
SD of three independent experiments). Statistical analyses were performed by the paired 
Student’s t-test (A-D) or One way Anova (E) (*P ≤ 0.05, **P ≤ 0.01).  
 
Figure 4. PTBP1 modulates alternative splicing of bladder cancer-related gene.  A) 
sqPCR of in vivo splicing assays performed in bladder cancer cell lines silenced with control 
(-) or PTBP1 (+) siRNAs of specific bladder-cancer gene targets. Schematic representation of 
alternative splicing events (left panel) analyzed is shown on the left. Exons (boxes), introns 
(lines) are indicated (left panel). The oncogenic splice variant is indicated (*) to the right of 
the agarose gel. B) Densitometric analysis (right graphs) of the splicing assays shown in (A) 
(mean±SD, n=3). Statistical analyses were performed by the paired Student’s t-test (* P ≤ 
0.05, ** P ≤ 0.01, *** P ≤ 0.001; ns: not significant). 
 
Figure 5. Inclusion of CD44 variable exons v5 and v7 correlates with PTBP1 expression 
in bladder cancer patients. A) PTBP1 expression assessed by immunohistochemistry 
analysis is expressed as percentage of positive cells. B) Pearson correlations between PTBP1 
and variable exons V5, V7 and V9 expression, assessed by qPCR analysis, in18 NMIBC 
patients.  
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Table 1. PTBP1 status according to clinical and pathological features and 
to clinical outcome of patients (n = 152) 
 
 
 
 
  
Variable PTBP1 Low: High: P°    n (%)  n (%) 
     
     
Age     
    ≤  65 17 (36.2) 33 (31.4) 0.580 
 
    > 65 30 (63.8) 72 (68.6)  
     
Gender     
     Male 36 (76.6) 84 (80.0) 0.670       Female 11 (23.4) 21 (20.0) 
     
pT classification     
     pTa   42 (89.4)   32 (30.5) <0.001*       pT1     5 (10.6)   73 (69.5) 
     
Tumor Grade     
    1-2  43 (91.5)   55 (52.4) <0.001*      3     4 ( 8.5)   50 (47.6) 
     
Risk of cancer progression     
    Low   21 (44.7)     6 ( 5.7) 
<0.001*      Intermediate   22 (46.8)   48 (45.7) 
    High      4 ( 8.5)   51 (48.6) 
     
Recurrence 32 (68.1) 41 (39.0) 0.001*      No 15 (31.9) 64 (61.0)  
    Yes     
     
Progression     
    No 47 (100.0) 94 (89.5) 0.021*      Yes   0    ( 0.0) 11 (10.5)  
     
Overall Survival     
    Death free   35 (74.5)   60 (57.1) 0.047*      Death from any cause   12 (25.5)   45 (42.9)  
     
Disease specific survival     
   Death free 47 (100.0)   95 (90.5) 0.029*     Death from bladder cancer   0    ( 0.0)   10 ( 9.5)  
     
°Pearson’s c2 test; *Statistically significant 
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